This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Michielin O, Van Akkooi A, Ascierto P, Dummer R, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019. doi: 10.1093/annonc/mdz411MichielinOVan AkkooiAAsciertoPDummerRKeilholzUESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201910.1093/annonc/mdz411Open DOISearch in Google Scholar
Cancer in Slovenia 2016. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2019.Cancer in Slovenia 2016LjubljanaInstitute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia2019Search in Google Scholar
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): cutaneus melanoma. Version 2.2019. [cited 2019 Sep 18]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfNational Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): cutaneus melanoma. Version 2.2019. [cited 2019 Sep 18]Available athttps://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfSearch in Google Scholar
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1239-51. doi: 10.1016/S1470-2045(19)30388-2RobertCRibasASchachterJAranceAGrobJJMortierLet alPembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyLancet Oncol20192012395110.1016/S1470-2045(19)30388-2Open DOISearch in Google Scholar
Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016; 36: 667-73. doi: 10.1016/S1470-2045(16)30578-2.LongGVGrobJJNathanPRibasARobertCSchadendorfDet alFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsLancet Oncol2016366677310.1016/S1470-2045(16)30578-2Open DOISearch in Google Scholar
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 2016: 22; 5487-96. doi: 10.1158/1078-0432.CCR-16-0127WeideBMartensAHasselJCBerkingCPostowMABisschopKet alBaseline biomarkers for outcome of melanoma patients treated with pembrolizumabClin Cancer Res20162254879610.1158/1078-0432.CCR-16-0127557256927185375Open DOISearch in Google Scholar
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ , Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582-8. doi: 10.1093/annonc/mdz011HamidORobertCDaudAHodiFSHwuWJKeffordRet alFive-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001Ann Oncol201930582810.1093/annonc/mdz011650362230715153Open DOISearch in Google Scholar
Schadendorf D, Livingstone E, Zimmer L. Treatment in metastatic melanoma - time to re-think. Ann Oncol 2019; 30: 501-3. doi: 10.1093/annonc/mdz050.SchadendorfDLivingstoneEZimmerLTreatment in metastatic melanoma - time to re-thinkAnn Oncol201930501310.1093/annonc/mdz05030768148Open DOISearch in Google Scholar
Amid MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eight edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9. doi: 10.3322/caac.21388.AmidMBGreeneFLEdgeSBComptonCCGershenwaldJEBrooklandRKet alThe eight edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer stagingCA Cancer J Clin20176793910.3322/caac.2138828094848Open DOISearch in Google Scholar
Gershenwald JE, Scolyer RA, Hess KR, Sondak Vk, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472-92. doi: 10.3322/caac.21409GershenwaldJEScolyerRAHessKRSondakVkLongGVRossMIet alMelanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA Cancer J Clin2017674729210.3322/caac.21409597868329028110Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRet alNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer2009452284710.1016/j.ejca.2008.10.02619097774Open DOISearch in Google Scholar
National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. [cited 2019 Oct 17]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdfNational Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. [cited 2019 Oct 17]Available athttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdfSearch in Google Scholar
Glitza Oliva IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastasis. Ann Oncol 2018; 29: 1509-20. doi: 10.1093/annonc/mdy185Glitza OlivaICSchvartsmanGTawbiHAdvances in the systemic treatment of melanoma brain metastasisAnn Oncol20182915092010.1093/annonc/mdy18529790899Open DOISearch in Google Scholar
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of pembrolizumab or programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; 36: 2872-8. doi: 10.1200/JCO.2018.79.0006ArbourKCMezquitaLLongNRizviHAuclinENiAet alImpact of baseline steroids on efficacy of pembrolizumab or programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancerJ Clin Oncol2018362872810.1200/JCO.2018.79.000630125216Open DOISearch in Google Scholar
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Eng J Med 2015; 372: 2521-32. doi: 10.1056/NEJMoa1503093RobertCSchachterJLongGVAranceAGrobJJMortierLet alPembrolizumab versus ipilimumab in advanced melanomaN Eng J Med201537225213210.1056/NEJMoa150309325891173Open DOISearch in Google Scholar
Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122: 3344-53. doi: 10.1002/cncr.30258AlgaziAPTsaiKKShoushtariANMunhozRRErogluZPiulatsJMet alClinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesCancer201612233445310.1002/cncr.30258576716027533448Open DOISearch in Google Scholar
Hamid O, Robert C, Ribas A, Stephen Hodi F, Walpole E, Daus A, et al. Anitumor activity of pembrolizumb in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018; 119: 670-4. doi: 10.1038/s41416-018-0207-6HamidORobertCRibasAStephenHodi FWalpoleEDausAet alAnitumor activity of pembrolizumb in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Br J Cancer2018119670410.1038/s41416-018-0207-6617374730202085Open DOISearch in Google Scholar
Vrankar M, Unk M. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol Oncol 2018 52: 365-9. doi: 10.2478/raon-2018-0037VrankarMUnkMImmune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapyRadiol Oncol201852365910.2478/raon-2018-0037628717330367809Open DOISearch in Google Scholar
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1. in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510-7. doi: 10.1200/JCO.2015.64.0391HodiFSHwuWJKeffordRWeberJSDaudAHamidOet alEvaluation of immune-related response criteria and RECIST v1.1. in patients with advanced melanoma treated with pembrolizumabJ Clin Oncol2016341510710.1200/JCO.2015.64.0391507054726951310Open DOISearch in Google Scholar
Urugel S, Rohmal J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 2017; 83: 247-57. doi: 10.1016/j. ejca.2017.06.028UrugelSRohmalJAsciertoPAFlahertyKTGrobJJHauschildAet alSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Eur J Cancer2017832475710.1016/j.ejca.2017.06.02828756137Open DOISearch in Google Scholar
Archibald W, Victor AI, Strawderman MS, Maggiore RJ. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience. J Geriatr Oncol 2019; 11. doi: 10.1016/j.jgo.2019.07.005ArchibaldWVictorAIStrawdermanMSMaggioreRJImmune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experienceJ Geriatr Oncol20191110.1016/j.jgo.2019.07.00531303463Open DOISearch in Google Scholar
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-74. doi: 10.1093/annonc/mdv623ChampiatSLambotteOBarreauEBelkhirRBerdelouACarbonnelFet alManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnn Oncol2016275597410.1093/annonc/mdv62326715621Open DOISearch in Google Scholar
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(Suppl 4): iv119-42. doi: 10.1093/annonc/mdx225HaanenJBAGCarbonnelFRobertCKerrKMPetersSLarkinJet alManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201728Suppl 4iv1194210.1093/annonc/mdx22528881921Open DOISearch in Google Scholar
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immnune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768. doi: 10.1200/JCO.2017.77.6385BrahmerJRLacchettiCSchneiderBJAtkinsMBBrassilKJCaterinoJMet alManagement of immune-related adverse events in patients treated with immnune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol2018361714176810.1200/JCO.2017.77.6385648162129442540Open DOISearch in Google Scholar
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563-80. doi: 10.1038/s41571-019-0218-0MartinsFSofiyaLSykiotisGPLamineFMaillardMFragaMet alAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceNat Rev Clin Oncol2019165638010.1038/s41571-019-0218-031092901Open DOISearch in Google Scholar
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018; 91: 21-9. doi: 10.1016/j.ejca.2017.12.008DanlosFXVoisinALDyevreVMichotJMRoutierETailladeVet alSafety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseEur J Cancer20189121910.1016/j.ejca.2017.12.00829331748Open DOISearch in Google Scholar
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blocade. N Eng J Med 2018; 378: 158-68. doi: 10.1056/NEJMra1703481.PostowMASidlowRHellmannMDImmune-related adverse events associated with immune checkpoint blocadeN Eng J Med20183781586810.1056/NEJMra170348129320654Open DOISearch in Google Scholar
Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and pre-existing autoimmune disorders. J Clin Oncol 2018; 36: 1905-12. doi: 10.1200/JCO.2017.77.0305LeonardiGCGainorJFAltanMKravetsSDahlbergSEGedmintasLet alSafety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and pre-existing autoimmune disordersJ Clin Oncol20183619051210.1200/JCO.2017.77.0305655384029746230Open DOISearch in Google Scholar
Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Global Oncol 2019; 5: 1-5. doi: 10.1200/JGO.19.00142RennerABurottoMRojasCImmune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?J Global Oncol201951510.1200/JGO.19.00142669065931348737Open DOISearch in Google Scholar
Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 2019; 30: 1154-61. doi: 10.1093/annonc/mdz110JansenYJLRozemanEAMasonRGoldingerSMGeukesFoppen MHHoejbergLet alDiscontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaAnn Oncol20193011546110.1093/annonc/mdz11030923820Open DOISearch in Google Scholar
Robert C, Ribas A, Hamid O, Daud A, Wolchok Jd, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018; 36: 1668-74. doi: 10.1200/JCO.2017.75.6270RobertCRibasAHamidODaudAWolchokJdJoshuaAMet alDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaJ Clin Oncol20183616687410.1200/JCO.2017.75.627029283791Open DOISearch in Google Scholar
Lorigan P, Eggermont AMM. Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. Ann Oncol 2019; 30: 1038-40. doi: 10.1093/annonc/mdz182LoriganPEggermontAMMAnti-PD1 treatment of advanced melanoma: development of criteria for a safe stopAnn Oncol20193010384010.1093/annonc/mdz18231218362Open DOISearch in Google Scholar
Daud AI, Wochok JD, Robert C, Hwu WJ, Weber JS, Ribas A, et al. Programmed death ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016; 34: 4102-9. doi: 10.1200/JCO.2016.67.2477DaudAIWochokJDRobertCHwuWJWeberJSRibasAet alProgrammed death ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanomaJ Clin Oncol2016344102910.1200/JCO.2016.67.2477556243427863197Open DOISearch in Google Scholar
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trial testing immunotherapeutics. Lancet Oncol 2017. 18: e143-52. doi: 10.1016/S1470-2045(17)30074-8SeymourLBogaertsJPerroneAFordRSchwartzLHMandrekarSet aliRECIST: guidelines for response criteria for use in trial testing immunotherapeuticsLancet Oncol201718e1435210.1016/S1470-2045(17)30074-8Open DOISearch in Google Scholar
Robert C, Long GV, Brandy B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med 2015; 372; 320-30. doi: 10.1056/NEJMoa1412082RobertCLongGVBrandyBDutriauxCMaioMMortierLet alNivolumab in previously untreated melanoma without BRAF mutationN Eng J Med20153723203010.1056/NEJMoa141208225399552Open DOISearch in Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five year survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med 2019; 381: 1535-46. doi: 10.1056/NEJMoa1910836LarkinJChiarion-SileniVGonzalezRGrobJJRutkowskiPLaoCDet alFive year survival with combined nivolumab and ipilimumab in advanced melanomaN Eng J Med201938115354610.1056/NEJMoa191083631562797Open DOISearch in Google Scholar
Forsea AM, Del Marmol V, Stratigos A, Geller AC. Melanoma prognosis in Europe: far from equal. Br J Dermatol 2014; 171: 179-82. doi: 10.1111/bjd.12923ForseaAMDel MarmolVStratigosAGellerACMelanoma prognosis in Europe: far from equalBr J Dermatol20141711798210.1111/bjd.1292324588115Open DOISearch in Google Scholar
